Skip to content
Menu

TScan Therapeutics, Inc. TCRX

Full chart Compare
Set alert

Price alert · TCRX

All alert types
0.14 USD -0.01 (-3.84%)

Regular-session close

0.15 +0.01 +4.98%

After hours · Nov 19, 6:41 PM ET

0.1401 Day range 0.157
0.14 52-week range 1.47
YTD
-85.73%
1 year
-86.15%

 

No chart data for this range yet.
Market cap
9.67M
Revenue (ttm)
9.36M
EPS (ttm)
-0.89
Shares out
49.09M
Forward P/E
-2.33
YTD return
-85.73%
1-year return
-86.15%
50-day average
4.58
200-day average
6.31
Volume
507.20K
Avg volume
759.48K
Open
0.1526
Previous close
0.1484
Day's range
0.1401 – 0.157
52-week range
0.14 – 1.47
Beta
0.78
Analysts
Strong Buy
Price target
12.14 (+8409.4%)

Key statistics

Enterprise value
-22.25M
Price / sales
17.16
Price / book
0.70
Revenue growth
-73.00%
Free cash flow
-71.11M
Total cash
271.12M
Total debt
90.36M
Return on equity
-55.92%
Short % of float
6.00%

Fundamental scorecard

7 of 25 checks passed on TCRX’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TCRX Revenue — quarterly 586.00K
TCRX Net income — quarterly -33.09M
TCRX EPS — quarterly -0.25

Earnings

TCRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.28-0.25+0.03+10.71%
Aug 12, 2024Jun 1, 2024-0.30———
Aug 12, 2024Jun 1, 2024-0.30-0.28+0.02+6.67%
May 13, 2024Mar 1, 2024-0.25-0.32-0.07-28.00%
May 13, 2024Mar 1, 2024-0.25———
Mar 6, 2024Dec 1, 2023-0.30———

Upgrades / downgrades

TCRX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024HC Wainwright & Co.reitBuyBuy
Dec 11, 2024NeedhamreitBuyBuy
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Nov 12, 2024NeedhamreitBuyBuy
Nov 6, 2024NeedhamreitBuyBuy
Aug 13, 2024WedbushreitOutperformOutperform

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
tscan.com

News

Your note

Sign in to keep a note on TCRX — it syncs with the Stock Master app.

Insider holders

TCRX insider holders
InsiderRelationLatest transactionDateShares held
BARBERICH TIMOTHY JOSEPHDirectorPurchaseDec 18, 2023100,286
KLENCKE BARBARA M.D.DirectorPurchaseSep 22, 202470,000
LYNX1 CAPITAL MANAGEMENT LPBeneficial Owner of more than 10% of a Class of SecurityPurchaseDec 12, 20240
SILVER BRIAN M.Chief Financial OfficerPurchaseDec 27, 202232,885
ZDRAVESKI ZORANOfficerSaleAug 22, 20244,716

Institution ownership

TCRX institution ownership
Holder% heldSharesValueReported
Lynx1 Capital Management Lp10.64%5,224,60015.73MSep 29, 2024
EcoR1 Capital, LLC10.18%5,000,00015.05MSep 29, 2024
Blackrock Inc.9.44%4,632,87613.94MSep 29, 2024
Adage Capital Partners GP L.L.C.8.96%4,400,00013.24MSep 29, 2024
BVF Inc.6.09%2,989,4749.00MSep 29, 2024
Baker Bros. Advisors, LP5.67%2,784,7928.38MSep 29, 2024

Fund ownership

TCRX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.79%1,370,3944.12MSep 29, 2024
Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF2.13%1,046,9163.15MSep 29, 2024
BlackRock Health Sciences Term Trust2.13%1,045,7673.15MSep 29, 2024
iShares Russell 2000 ETF1.97%967,4772.91MOct 30, 2024
Blackrock Funds-Health Sciences Opportunity Portfolio1.39%681,0152.05MAug 30, 2024
Vanguard Extended Market Index Fund1.31%645,5101.94MSep 29, 2024